Latest news

• FDA panel backs Pfizer and Teva abuse-resistant painkillers

  The panel also voted by nine votes to six in favour of approving Pfizer's Troxyca ER (oxycodone/naltrexone) for the sane indication. ... In the case of Troxyca ER, the inclusion of opioid blocker naltrexone is designed to achieve the same end result.

• Takeda files block on generic diet pill launch

  The lawsuit alleges that the generic drugmaker Actavis has infringed patents on Orexigen and Takeda's new weight-loss treatment Contrave (naltrexone and bupropion).

• Saxenda debuts in US with $1,000-a-month price tag

  s Contrave (bupropion/naltrexone), Arena/Eisai's Belviq (lorcaserin) and Vivus' Qsymia (phentermine/topiramate), although for patients the monthly cost will fall depending on their insurance cover. .

• Positive data in Saxenda diabetes prevention study

  the US of three other drugs; Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion).

• CHMP thumbs up for Novo's obesity drug Saxenda

  new products - Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion) in the last couple of years in the US and other world